← Human Trials & Peer-Reviewed Studies
The effects of short term recombinant human growth hormone (rhGH) on blood rheology in healthy young males.
Plain-language guide to PMID 21339632 (2011): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 21339632
- Journal
- Clinical hemorheology and microcirculation
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Ramos SB et al. (7 authors)
- DOI
- 10.3233/CH-2010-1373
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
GH stimulates the production of insulin-like growth factor I (IGF-I) and GH-IGF-I system has profound effects on body fluid status.
There are speculations that GH has become widely used as a performance enhancing drug among athletes of various sports.
Who Took Part
PubMed indexes the participants as young adults and adults, men only.
How the Study Was Run
The design is described as randomized and placebo-controlled.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
This study evaluated plasma fibrinogen levels, red blood cell (RBC) aggregation, deformability and serum IGF-I levels between and within the groups along 29 days.
What Was Measured
The present study evaluated the possible hemorheological effects of short term administration of human recombinant growth hormone (rhGH) in healthy young males.
Topics PubMed links to this paper include Erythrocyte Aggregation, Erythrocyte Deformability, Fibrinogen, Hemorheology, Human Growth Hormone, Insulin-Like Growth Factor I and Performance-Enhancing Substances.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Results are reported in around 1 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2011 (Clinical hemorheology and microcirculation), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.